

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following statements is true regarding PI3K inhibitors under investigation for ER-positive mBC?
  - They are associated with diarrhea, hyperglycemia and pneumonitis
  - They do not elicit objective responses when administered as monotherapy
  - Both a and b
  - Neither a nor b
- In the Phase II PERTAIN trial investigating trastuzumab with an aromatase inhibitor with or without pertuzumab as first-line therapy for hormone receptor-positive, HER2-positive locally advanced or metastatic breast cancer, the addition of pertuzumab resulted in a significant improvement in progression-free survival.
  - True
  - False
- The TRINITY-1 trial is assessing everolimus and exemestane in combination with \_\_\_\_\_ for patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after disease progression on a CDK4/6 inhibitor.
  - Taselisib
  - Abemaciclib
  - Ribociclib
- The FALCON trial evaluating fulvestrant versus anastrozole for postmenopausal patients with locally advanced or metastatic hormone receptor-positive breast cancer who had not received previous endocrine therapy demonstrated superior efficacy with anastrozole.
  - True
  - False
- The stomatitis associated with everolimus \_\_\_\_\_.
  - Appears early in the course of treatment
  - Can be prevented in some cases with a prophylactic mouthwash
  - Can be managed with dose reduction
  - All of the above
  - Both a and b
- Which of the following statements is true regarding the CDK4/6 inhibitor abemaciclib?
  - It does not demonstrate single-agent activity
  - It is active in patients with hormone receptor-positive, HER2-negative breast cancer and brain metastases
  - It is administered on a continuous schedule
  - All of the above
  - Both b and c
- The CDK4/6 inhibitor ribociclib \_\_\_\_\_.
  - Is administered on a 3 weeks on, 1 week off schedule
  - Seems to be associated with less cardiac toxicity in comparison to palbociclib
  - Both a and b
- The Phase II monarchHER trial for patients with hormone receptor-positive, HER2-positive locally advanced or metastatic breast cancer is comparing the CDK4/6 inhibitor \_\_\_\_\_ in combination with trastuzumab with or without fulvestrant to chemotherapy and trastuzumab.
  - Ribociclib
  - Abemaciclib
  - Taselisib
- Patients with ER-positive advanced breast cancer who harbor ESR1 mutations are more likely to respond to \_\_\_\_\_.
  - Anastrozole
  - Fulvestrant
  - Letrozole
  - All of the above
- Strategies for the management of neutropenia associated with palbociclib include \_\_\_\_\_.
  - Withholding the drug
  - Dose reductions
  - Switching to abemaciclib
  - All of the above
  - Both a and b